Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03161028 · ClinicalTrials.gov registry record · Phase 2
Lipoic Acid for Progressive Multiple Sclerosis (MS)
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT03161028: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03161028 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 115 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03161028, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
Interventions
- DRUG Placebo
- DRUG Lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2018-08-17 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03161028
The ClinicalTrials.gov registry entry for NCT03161028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03161028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03161028 about?
NCT03161028 is a clinical study titled "Lipoic Acid for Progressive Multiple Sclerosis (MS)". The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.
What is the current status of trial NCT03161028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2018-08-17. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT03161028?
The interventions under investigation include: Placebo (DRUG), Lipoic acid (DRUG).
Who is sponsoring clinical trial NCT03161028?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.